BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 35732352)

  • 1. A population-based study of outcomes in adjuvant radiotherapy for stage II endometrial carcinoma.
    Moldovan N; Lambert P; Ong A; Altman AD
    Int J Gynecol Cancer; 2022 Jun; ():. PubMed ID: 35732352
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Low-dose adjuvant vaginal cylinder brachytherapy for early-stage non-endometrioid endometrial cancer: recurrence risk and survival outcomes.
    Smart A; Buscariollo D; Alban G; Buzurovic I; Cheng T; Pretz J; Krechmer B; King M; Lee L
    Int J Gynecol Cancer; 2020 Dec; 30(12):1908-1914. PubMed ID: 32655012
    [TBL] [Abstract][Full Text] [Related]  

  • 3. External beam radiotherapy versus vaginal brachytherapy in patients with stage II endometrial cancer: a systematic review and meta-analysis.
    Narasimhulu DM; Cope A; Riaz IB; Petersen I; Cilby W; Langstraat C; Glaser G; Kumar A; Cappuccio S; Murad MH; West C; Mariani A
    Int J Gynecol Cancer; 2020 Jun; 30(6):797-805. PubMed ID: 32221021
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Outcomes and relapse patterns of stage IB grade 2 or 3 endometrial cancer treated with adjuvant vaginal brachytherapy.
    Hochreiter A; Kelly JR; Young MR; Litkouhi B; Black JD; Stromberger C; Higgins S; Schwartz PE; Damast S
    Int J Gynecol Cancer; 2020 Jan; 30(1):48-55. PubMed ID: 31722964
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intravaginal brachytherapy alone for intermediate-risk endometrial cancer.
    Alektiar KM; Venkatraman E; Chi DS; Barakat RR
    Int J Radiat Oncol Biol Phys; 2005 May; 62(1):111-7. PubMed ID: 15850910
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of different adjuvant radiotherapy modalities on women with early-stage intermediate- to high-risk endometrial cancer.
    Jin M; Hou X; Sun X; Zhang Y; Hu K; Zhang F
    Int J Gynecol Cancer; 2019 Oct; 29(8):1264-1270. PubMed ID: 31320487
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adjuvant radiotherapy in Stage II endometrial carcinoma: Is brachytherapy alone sufficient for local control?
    Paydar I; DeWees T; Powell M; Mutch DG; Grigsby PW; Schwarz JK
    Brachytherapy; 2015; 14(4):427-32. PubMed ID: 25911995
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multi-institutional Analysis of Vaginal Brachytherapy Alone for Women With Stage II Endometrial Carcinoma.
    Harkenrider MM; Martin B; Nieto K; Small C; Aref I; Bergman D; Chundury A; Elshaikh MA; Gaffney D; Jhingran A; Lee L; Paydar I; Ra K; Schwarz J; Thorpe C; Viswanathan AN; Small W
    Int J Radiat Oncol Biol Phys; 2018 Aug; 101(5):1069-1077. PubMed ID: 29885996
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of vaginal brachytherapy boost following adjuvant external beam radiotherapy in cervical cancer: Turkish Society for Radiation Oncology Gynecologic Group Study (TROD 04-002).
    Gultekin M; Beduk Esen CS; Balci B; Alanyali S; Akkus Yildirim B; Guler OC; Yuce Sari S; Ergen SA; Sahinler I; Alsan Cetin I; Onal C; Yildiz F; Ozsaran Z
    Int J Gynecol Cancer; 2021 Feb; 31(2):185-193. PubMed ID: 32998860
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adjuvant treatment improves overall survival in women with high-intermediate risk early-stage endometrial cancer with lymphovascular space invasion.
    Son J; Chambers LM; Carr C; Michener CM; Yao M; Beavis A; Yen TT; Stone RL; Wethington SL; Fader AN; Burkett WC; Richardson DL; Staley AS; Ahn S; Gehrig PA; Torres D; Dowdy SC; Sullivan MW; Modesitt SC; Watson C; Veade A; Ehrisman J; Havrilesky L; Secord AA; Loreen A; Griffin K; Jackson A; Viswanathan A; Ricci S
    Int J Gynecol Cancer; 2020 Nov; 30(11):1738-1747. PubMed ID: 32771986
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of vaginal recurrences in endometrial carcinoma by high-dose-rate brachytherapy.
    Sorbe B; Söderström K
    Anticancer Res; 2013 Jan; 33(1):241-7. PubMed ID: 23267151
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Local recurrence in high-risk node-negative stage I endometrial carcinoma treated with postoperative vaginal vault brachytherapy.
    Ng TY; Perrin LC; Nicklin JL; Cheuk R; Crandon AJ
    Gynecol Oncol; 2000 Dec; 79(3):490-4. PubMed ID: 11104626
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adjuvant high dose rate vaginal brachytherapy as treatment of stage I and II endometrial carcinoma.
    Horowitz NS; Peters WA; Smith MR; Drescher CW; Atwood M; Mate TP
    Obstet Gynecol; 2002 Feb; 99(2):235-40. PubMed ID: 11814503
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vaginal brachytherapy versus pelvic external beam radiotherapy for patients with endometrial cancer of high-intermediate risk (PORTEC-2): an open-label, non-inferiority, randomised trial.
    Nout RA; Smit VT; Putter H; Jürgenliemk-Schulz IM; Jobsen JJ; Lutgens LC; van der Steen-Banasik EM; Mens JW; Slot A; Kroese MC; van Bunningen BN; Ansink AC; van Putten WL; Creutzberg CL;
    Lancet; 2010 Mar; 375(9717):816-23. PubMed ID: 20206777
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Toxicity, recurrence and survival after adjuvant radiotherapy treatment for FIGO stage I cancer of the endometrium.
    Moss EL; Stevens A; Gray L; McConkey C; Fernando I
    Clin Oncol (R Coll Radiol); 2003 Aug; 15(5):250-4. PubMed ID: 12924455
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PORTEC-4a: international randomized trial of molecular profile-based adjuvant treatment for women with high-intermediate risk endometrial cancer.
    van den Heerik ASVM; Horeweg N; Nout RA; Lutgens LCHW; van der Steen-Banasik EM; Westerveld GH; van den Berg HA; Slot A; Koppe FLA; Kommoss S; Mens JWM; Nowee ME; Bijmolt S; Cibula D; Stam TC; Jurgenliemk-Schulz IM; Snyers A; Hamann M; Zwanenburg AG; Coen VLMA; Vandecasteele K; Gillham C; Chargari C; Verhoeven-Adema KW; Putter H; van den Hout WB; Wortman BG; Nijman HW; Bosse T; Creutzberg CL
    Int J Gynecol Cancer; 2020 Dec; 30(12):2002-2007. PubMed ID: 33046573
    [TBL] [Abstract][Full Text] [Related]  

  • 17. How deep is too deep? Assessing myometrial invasion as a predictor of distant recurrence in stage I endometrioid endometrial cancer.
    Dinoi G; Garzon S; Weaver A; McGree M; Glaser G; Langstraat C; Kumar A; Weroha J; Garda AE; Shahi M; Palmieri E; Scambia G; Fanfani F; Mariani A
    Int J Gynecol Cancer; 2024 May; ():. PubMed ID: 38821549
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of adjuvant therapy in stage IIIC2 endometrial cancer.
    Bogani G; Cappuccio S; Casarin J; Narasimhulu DMM; Cilby WA; Glaser GE; Weaver AL; McGree ME; Keeney GL; Weroha J; Petersen IA; Mariani A
    Int J Gynecol Cancer; 2020 Aug; 30(8):1169-1176. PubMed ID: 32646864
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Stage II endometrial carcinoma: limiting post-operative radiotherapy to the vaginal vault in node-negative tumors.
    Rittenberg PV; Lotocki RJ; Heywood MS; Krepart GV
    Gynecol Oncol; 2005 Sep; 98(3):434-8. PubMed ID: 16005498
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adenocarcinoma of the endometrium treated with combined irradiation and surgery: study of 437 patients.
    Touboul E; Belkacémi Y; Buffat L; Deniaud-Alexandre E; Lefranc JP; Lhuillier P; Uzan S; Jannet D; Uzan M; Antoine M; Huart J; Ganansia V; Milliez J; Blondon J; Housset M; Schlienger M
    Int J Radiat Oncol Biol Phys; 2001 May; 50(1):81-97. PubMed ID: 11316550
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.